Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma By Ogkologos - July 9, 2026 61 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SUCCESSOR-2 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Datopotamab Deruxtecan High-Dose Chemotherapy Followed by ASCT Improves Survival Compared with Non-myeloablative Consolidation in Primary CNS Lymphoma Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced RCC Following Progression to PD1 or PD-L1 Inhibitors MOST POPULAR Screen-Detected Colorectal Cancers Have a More Favourable Stage Distribution than Colorectal... May 20, 2022 FDA Approves Cabozantinib for Differentiated Thyroid Cancer September 30, 2021 FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof... March 23, 2026 Woman Celebrates Beating Cancer By Creating Christmas Tree Mannequins With A... December 6, 2019 Load more HOT NEWS Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not... Durvalumab Plus Chemotherapy Improves Survival in Small Cell Lung Cancer How keeping active during cancer treatment has helped Mary and Keith Study in India Could Make Immunotherapy More Affordable Worldwide
